A review of published evidence reporting on the efficacy and pharmacology of lurasidone

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 11, 2012, Pages 1653-1659

  McIntyre, Roger S ^a   Cha, Danielle S ^a   Alsuwaidan, Mohammad ^a   McIntosh, Diane ^b   Powell, Alissa M ^a   Jerrell, Jeanette M ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Lurasidone; Metabolic; Schizophrenia; Weight gain

Indexed keywords

ARIPIPRAZOLE; CISPLATIN; CLOZAPINE; DIZOCILPINE; LURASIDONE; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE;

AGITATION; AKATHISIA; ANTHROPOMETRY; ANXIETY; APPETITE; BACKACHE; BIPOLAR DEPRESSION; BODY COMPOSITION; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; HEADACHE; HUMAN; INSOMNIA; MUSCLE STIFFNESS; NAUSEA; NONHUMAN; PARKINSONISM; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SALIVATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TOOTH PAIN; VOMITING; WEIGHT GAIN; XEROSTOMIA;

BIPOLAR DISORDER; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COGNITION DISORDERS; DOUBLE-BLIND METHOD; HUMANS; ISOINDOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; THIAZOLES;

EID: 84863789593     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.683174     Document Type: Review

References (14)

1. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210
2. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171-81
3. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011;338(2):605-14
4. Galici R, Boggs JD, Miller KL, et al. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 2008;19(2):153-9
5. Horiguchi M, Huang M, Meltzer HY. Interaction of mGlu/agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011;217(1):13-24
6. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572(2-3):160-70
7. Horisawa T, Ishibashi T, Nishikawa H, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: Mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 2011;220(1):83-90
8. Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186(2):197-207
9. Lee KR, Chae YJ, Koo TS. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica 2011;41(12):1100-7
10. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168(9):957-67
11. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
12. Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 2011;132(2-3):101-7
13. Loebel A, Cucchiaro J, Sarma K, et al. Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial (PEARL 3). 12-5-2010
14. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011;127(1-3):188-94